This close to Top Line results 3 to 8 weeks out the Heavy money will expect the share price to appreciate and will use all the available tool shed devices in order to see return on investment. Two competing forces will be at work If it hits before the close of Q4. Those that want a good end to the Q and those that want in for Q1-016
3users liked this postsusers disliked this posts0Reply
What a difference a couple weeks make.
WASH ? Short Term ?
Do you suppose the 86% TUTE ownership will take your advice?
by atm21money • Nov 12, 2015 9:25 PM
Is Dynavax setting the stage to secure the $90 Million knowing that its a drop in the bucket as far as market cap is concerned given the expected blow out trial results and its affect on causing the PPS and Market Cap to rise significantly shortly after the results are released in Dec / Jan? They might be thinking that no one will care about the dilution if the trial results exceeds expectations and the chance of approval is nearly guaranteed so now is the perfect time to raise the money with all the hype surrounding the stock with an expected successful phase III trial results. Could this new ATM actually be a boost for the stock in that the market might after careful analysis come to similar conclusion that these guys have some very good news to report fairly soon? Santa Clause rally........ Time to Cash with our outstanding trials results.
They would be adding a mere 2.57 Million shares to our existing 38.4 Million shares outstanding which is a small adder if the stock trades around $35 - $40 range per share after the trial results are released in December. Lets see if they hold off selling shares until after the trial results are released and the stock rockets upward and get in the $35 or so range. If they sell before hand, I would worry about the trial results as they would be adding more shares to raise $90 Million than if they waited until after the results are released assuming the results are favorable.
Their stock options become more valuable if they add fewer shares to their outstanding totals as the value for each share would be higher if fewer shares are outstanding. Are these guys smart? We will see. Less
Sentiment: Strong Buy
If the FED has the Debbie Downers as bad as you in terms of Recession And Disappointments
They would not Hike.
Question do you see yourself changing your day to day Monetary habits before the end of the year because of anything on your list?
Interesting Date DEC 16th
Remember those 7,500 DEC 30.00 Calls, they close on DEC 18th
Exactly do you mean by " TRADE CAUTIOUSLY " ?
In the Sep 10 presentation of DVAX at the Newsmakers in the Biotech Industry Conference, Michael Ostrach said that its phase 1b clinical trial in co-therapy with Keytruda (MRK's FDA-approved PD-1 inhibitor) is about to begin. Also, he said that he expected the SD-101's effect on DVAX to be TRANSFORMATIVE.
—The search for ways to create immunotherapy combinations—one-two punches to beat stubborn cancers—continued apace, with news of deals released to coincide with the ASCO spotlight. Merck, for instance, cut separate deals with Dynavax Technologies (NASDAQ: DVAX) and Tesaro (NASDAQ: TSRO) to test pembrolizumab in combination with Dynavax’s toll-like receptor-modulating drug SD-101; and with Tesaro’s niraparib, part of a class of drugs called PARP inhibitors.
Arnold Lewis Oronsky, PhD
Age : 75
Linked companies :
Dynavax Technologies Corporation - Chairman
TESARO Inc - DR Dr. Arnold L. Oronsky is Independent Director
TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which has completed phase 3 oral formulation trials, as well as is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor that is in phase 3 clinical trials to treat ovarian cancer; and TSR-011, an orally available anaplastic lymphoma kinase inhibitor, which is in phase 1/2a dose escalation clinical trial in cancer patients. The company also offers KEYTRUDA, a programmed cell death protein 1 antibody for the treatment of certain melanomas. TESARO, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
ORBIMED'S holding with TESARO
Orbimed Advisors LLC. 1,735,200 shares Value 69,581,516 9/30/15
ORBIMEB'S holding with DVAX
Orbimed Advisors LLC. 2,472,200 shares Value 60,667,790 9/30/15
TIC TOC *
Jim you BASH BASH BASH anyone and that would include 50% of the shares held long by TUTS
You might review what's in the mirror *
50% of the TUTS shares INVESTED HELD / Rode it around *
Corvus’s most advanced medicine is also a checkpoint inhibitor. Unlike the antibody drugs Opdivo, Keytruda and Yervoy, which are taken intravenously, Corvus’s product is a small-molecule drug taken orally. It also targets a different checkpoint protein, Dr. Miller said, although he didn't disclose which one. Having an oral product targeting a different checkpoint protein gives Corvus a competitive advantage, according to Dr. Miller.
The drug may be effective on its own and in combination with anti-PD-1 or PD-L1 drugs, according to Dr. Miller. Corvus intends to initiate Phase Ib clinical trials in solid-tumor patients in early 2016.
Corvus’s other programs include a preclinical drug that reprograms T cells to make them more toxic to tumor cells. The company, based in Burlingame, Calif., also has an early-stage antibody checkpoint inhibitor and an early-stage small-molecule checkpoint inhibitor, Dr. Miller said.
ORBIMED'S Dr. Thompson has joined the Corvus board along with Novo Ventures Partner Peter Moldt and Adams Street Partner Terry Gould.
July 1, 2015
Resource's & Dot connection
Former Pharmacyclics CEO Raises $33.5M Series A for Corvus Pharmaceuticals
Venture firms are betting that the founding chief executive of Pharmacyclics Inc., acquired by AbbVie Inc. for $21 billion, will develop another blockbuster cancer therapy through newly formed Corvus Pharmaceuticals Inc.
Richard A. Miller launched Corvus last year and raised a $33.5 million Series A round in December led by ORBIMED Advisors. With Pharmacyclics, formed in 1991, he initiated a program to develop Imbruvica, a blood cancer therapy that won initial U.S. approval in 2013. Imbruvica's ability to treat diseases such as chronic lymphocytic leukemia led AbbVie to buy Pharmacyclics in May.
Dr. Miller, who was Pharmacyclics CEO until September 2008, teamed up with former Pharmacyclics executive Joseph J. Buggy and OrbiMed Private Equity Partner Peter Thompson to form Corvus. The company, also funded by Adams Street Partners and Novo Ventures, develops immuno-oncology drugs that help the immune system combat cancer.
Immuno-oncology has emerged recently as scientists have uncovered new ways to tap into the immune system’s power. Immuno-oncology therapies are leading to advances in the treatment of diseases such as melanoma, lung cancer and various blood cancers. This is leading venture investors to fund several different approaches to immuno-oncology.
Companies like Juno Therapeutics Inc., which went public in December, engineer T cells of the immune system to battle cancer. Others, including CytomX Therapeutics Inc., are developing “checkpoint inhibitors,” or drugs that release a brake that keeps the immune system from attacking cancer. CytomX is developing a drug targeting the checkpoint molecule PD-L1.
Marketed drugs Opdivo and Keytruda, from Bristol-MyersSquibb Co. and Merck & Co., respectively, inhibit a similar checkpoint target, PD-1. Another approved product, Bristol-Myers's Yervoy, blocks the checkpoint protein CTLA-4.
Corvus’s most advanced m
I don't actually read your long winded post But this one I found interesting.
" Here are the FACTS:
Total Institutional Shares-----159-----32,971,491
PLEASE NOT THIS---ONLY 10 rode the stock---TEN.
10/159 = 6% HELD and RODE----The other 94% traded it. "
Jim that 6% HELD 50 % of the shares 1/2 Bro
The reduction in SI doesn't help your Tute theory with where we are in relation to the closing of a study.
Rumor has it BETA is about to drop 1.0 Or lower